 Secondary objectives: i to identify the subclinical organ damage profile at baseline and its association with OSA, and to identify if long term blood pressure control and number of antihypertensive drugs needed is different depending on OSA diagnosis and its treatment; ii to identify epigenetic profiles and clinical, biological and polygraphic variables with a predictive value for cardiovascular outcomes in RH patients with OSA; iii to validate the HIPARCO-SCORE tool in men in an independent cohort and elaborate a new tool to be used in women; and iv to perform a cost-effectiveness analysis to evaluate the impact of OSA diagnosis and treatment in patients with RH. 